The 43rd Annual Meeting of the Japan Neuroscience Society

Presentation information

Poster

Disorders of Nervous Systems and Treatment

[3P] Alzheimer's Disease and Dementia

Fri. Jul 31, 2020 1:30 PM - 3:30 PM Poster Session

[3P-212] Cannabinoid receptor type II in microglia as a therapeutic target for Alzheimer's disease

*Akira Sobue1, Okiru Komine1, Fumito Endo1, Shigeo Murayama2, Takashi Saito3, Takaomi Saido4, Koji Yamanaka1 (1.Dept of Neurosci. and Pathobiol., RIEM, Nagoya Univ., Nagoya, Japan, 2.Dept of Neuropathol., Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan, 3.Department of Neurocognitive Science, Nagoya City University, Nagoya, Japan, 4.Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan)

Alzheimer's disease (AD) is the most common form of dementia, characterized by accumulation of amyloid β (Aβ) and phosphorylated Tau. Current therapies for AD are aimed to correct synaptic malfunction of neurons based on the cholinergic hypothesis. These therapies treat the symptoms but do not modify the progression of the disease. On the other hand, neuroinflammation, mediated by activation of glial cells such as astrocytes and microglia, is considered to play an important role in the progression of AD. However, the extent to which these events contribute to the Aβ pathologies remains to be determined. In this study, we performed next-generation sequence analysis using RNAs derived from the precuneus of patients with AD, which is selectively vulnerable to amyloid deposition at the early stage, and RNAs derived from microglia isolated from cerebral cortices of 4, 8 and 12-month-old AppNL-G-Fmice by using magnetic-activated cell sorting. The expression of cannabinoid receptor type II (CB2) gene was commonly altered in these samples. CB2, mainly expressed in peripheral immune cells and CNS microglia, contributes to modulate inflammation. To elucidate the role of CB2 in the CNS, we analyzed the primary microglia and AppNL-G-Fmice using JWH133, a selective CB2 agonist. JWH133 negatively regulated the RNA expression levels of inflammatory cytokines such as TNF-α and CXCL10 in IFN-γ-stimulated microglia in vitro. In addition, chronic oral administration of JWH133 significantly ameliorated the cognitive impairments of AppNL-G-Fmice in the novel object recognition test. JWH133-treated AppNL-G-Fmice also showed significant decrease of activated (A1) astrocyte's markers and microglial C1q, one of inducers for the A1 astrocyte, compared to vehicle-treated AppNL-G-Fmice. These results suggest that stimulating microglial CB2 ameliorates cognitive dysfunction in AppNL-G-Fmice through controlling astrocyte activation and inducing beneficial neuroinflammation.